Hummingbird Ventures invests in Healthleap
Funding Provisional 90% confidence first seen
Healthleap raised $38 million in funding, including a $30 million Series A led by Hummingbird Ventures (with an $8 million seed co-led by Sequoia Capital and First Round Capital). The company is building an AI platform that reads hospital inpatients’ records to flag patients who may have undiagnosed conditions for additional clinician review. The investment matters because it accelerates Healthleap’s expansion of its engineering, product, and commercial efforts as it broadens from initial programs such as malnutrition and delirium to more conditions.
The deal
Healthleap $38M Series A · announced 7 Oct 2026
Investors Sequoia Capital First Round Capital Hummingbird Ventures
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Healthleap raised $38 million, including a $30 million Series A led by Hummingbird Ventures and an earlier $8 million seed co-led by Sequoia Capital and First Round Capital. The company said it is using the funding to expand its AI platform that reviews hospital inpatient records to flag possible undiagnosed conditions for clinician follow-up and to grow engineering, product, sales, and customer success.
- Why it matters
- For healthcare and AI leaders, this financing gives Healthleap more capacity to commercialize and scale a clinical-records screening product aimed at hospital workflow, which could intensify competition in AI-assisted inpatient decision support. The raise also signals investor appetite for narrowly targeted clinical AI tools tied to specific use cases, as Healthleap is expanding from malnutrition and delirium into additional conditions.
- Evidence
- The information comes from a TechCrunch report that states the size of the rounds, the lead and co-lead investors, the product focus, and the intended use of proceeds. Coverage is based on a single outlet, so the core facts are supported but not independently corroborated across multiple reports in the provided material.
- What remains uncertain
- The coverage does not provide adoption metrics, hospital customer count, clinical outcomes, regulatory positioning, or details on which new conditions Healthleap will target next. It is therefore unclear how differentiated the product is in practice, how quickly expansion will translate into revenue or deployments, and what implementation burden hospitals face.
- Monitor next
- Watch for announced hospital deployments or published outcome data showing whether Healthleap’s platform improves detection rates or workflow efficiency beyond its initial malnutrition and delirium programs.
Analytical support, not advice — assumptions and open questions stated above.